What is MDClone?
MDClone operates at the intersection of technology and healthcare, providing a robust platform designed to unlock the potential of complex healthcare data. The company's innovative approach facilitates exploration, discovery, and collaboration, enabling a more profound understanding of patient health. By offering a secure and intuitive environment for data analysis, MDClone empowers healthcare professionals and researchers to derive actionable insights, driving advancements in medical research and clinical practice. The firm's commitment to data integrity and user-centric design positions it as a key player in the digital health transformation.
How much funding has MDClone raised?
MDClone has raised a total of $99M across 3 funding rounds:
Series A
$10M
Series B
$26M
Series C
$63M
Series A (2018): $10M with participation from OrbiMed and Lightspeed Venture Partners
Series B (2019): $26M, investors not publicly disclosed
Series C (2022): $63M supported by Warburg Pincus and Viola Growth
Key Investors in MDClone
Warburg Pincus
Warburg Pincus LLC is a leading global private equity firm renowned for its expertise in growth investing. Operating as a private partnership, the firm leverages decades of experience to support investors and management teams in building long-term, sustainable success across diverse market cycles.
Viola Growth
Viola Growth is an Israeli-based technology growth capital fund that specializes in investing in global companies at the expansion phase. The fund focuses on propelling Israeli startups through their growth stages, offering financial and operational expertise to develop robust growth strategies.
OrbiMed
OrbiMed Advisors LLC operates as a specialized investment firm focused on the healthcare sector, with deep expertise spanning multiple therapeutic and commercial domains. The firm manages capital across biopharmaceuticals, medical devices, digital health platforms, diagnostics, and healthcare services.
What's next for MDClone?
With the recent infusion of $63M in major strategic investment, MDClone is poised for significant expansion and further development of its data exploration platform. This capital injection, contributing to the company's overall $99M in funding, will likely fuel advancements in AI-driven analytics, broaden its market reach, and enhance its collaborative features. The company's trajectory suggests a focus on scaling its operations to meet the growing global demand for accessible and secure healthcare data solutions. Strategic partnerships and continued innovation in data science are anticipated as MDClone solidifies its position as a leader in healthcare data democratization.
See full MDClone company page
